Therefore, although the oral cancer patients who carried the MET rs33917957 polymorphisms showed no statistically significant association of clinical variables such as the clinical stage and TNM staging in our study, and most of the oral cancer patients enrolled in our study are individuals without lymph node metastasis, the MET rs33917957 may hence be interpreted as an early marker to evaluate cancer progression and prognosis oral cancer. The gene discussed is MET; the disease is metastatic malignant neoplasm in the lymph nodes.